Startups set off new wave of mRNA therapeutics
Elie Dolgin • Sep 02, 2021
After the vaccine triumphs of Pfizer/BioNTech and Moderna, a raft of startups is developing mRNA, circular RNA and self-amplifying RNA therapeutics.
A cadre of new startups are building next-generation RNA platform technologies designed to solve some of the unique challenges associated with using conventional mRNA tools as therapeutics.
Read more at Nature Biotechnology.
Drug trial results show that vaccines aren't the only use for the mRNA technology behind the most widely used COVID-19 jabs.
FDA panel’s green light on glaucoma wearable device offers hope in sight.